Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records reported in 2004

5 records with a recorded report or completion year of 2004.

Showing 0 records on this page

Records

5 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
TA1-HCV-1Thymosin alpha-1Phase 3ReportedRandomised, double-blind, active-controlled2004Moderate
TA1-HCV-1-BODY-COMPprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2004Very low
TA1-HCV-1-QOLprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2004Very low
TA1-HCV-1-REGIONAL-CNprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2004Very low
TA1-HCV-1-REGIONAL-JPprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2004Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.